+ Classes of Molecules (ºÐÀÚÀÇ ºÐ·ù)
- Small molecules (¼ÒÇü ºÐÀÚ)
- Peptides and proteins (´Ü¹éÁú)
- Oligonucleotides (¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå)
- Carbohydrates (ź¼öȹ°)
- Natural products (õ¿¬Á¦Ç°)
+ Formulation Services (Á¦Ç° ¼ºñ½º)
- Preformulation and formulation (ÃʱâÁ¦Á¶ ¹× Á¦Ç°)
- Formulation feasibility studies (Á¦Á¶ °¡´É¼º ¿¬±¸)
- Excipient compatibility (Excipient ÀûÀÀ¼º)
- Container/closure evaluations (¿ë±â/ÆóÆ÷ Æò°¡)
- Device options (ÀåÄ¡ ¿É¼Ç)
- Drug product and process components compatibility (¾àǰ°ú Á¦Ç° ±¸¼º¼ººÐ)
- Physico-chemical testing (¹°¸® ÈÇÐ ½ÃÇè)
- Lyophilization and sterilization cycle development (Lyophilization ¹× ¸ê±ÕÁֱ⠰³¹ß)
- Stability evaluations (¾ÈÁ¤¼º Æò°¡)
+ Technical Capabilities (±â¼úÀû ´É·Â)
+ Aerosol Formulations/Delivery Systems (¿¡¾î·ÎÁ¹ °ø½Ä/ ¹è´Þ)
- Metered dose inhalers (pMDIs) (°è·® ³óµµ ÈíÀÔ±â)
- Dry powder inhalers (DPIs) (°ÇÁ¶µÈ ÆÄ¿ì´õ ÈíÀÔ±â)
- Liquid inhalers (¾×ü ÈíÀÔ±â)
- Nasal sprays (ÄÚ ºÐ¹«±â)
- Nebulizers (ºÐ¹«±â)
+ Parenteral Formulations (ºñ°æ±¸ÀûÀÎ Á¦Ç°)
- Lyophilized products (Lyophilized Á¦Ç°)
- Solutions (¿ë¾×)
- Suspensions/emulsions (Çöʾ×/À¯»ó¾×)
+ Oral Formulations (°æ±¸¿ë Á¦Ç°)
- Tablets (Á¤Á¦)
- Capsules (ĸ½¶)
- Liquids (¾×ü)
+ Topical Formulations (±¹¼ÒºÎÀ§ Á¦Ç°)
- Gels (Á©)
- Ointments (¿¬°í)
- Creams (Å©¸²)
+ Drug Delivery Technologies (¾à¹° Àü´Þ ±â¼ú )
- Controlled/sustained release (Á¦¾î ¹æÃ⠽ýºÅÛ)
- Delivery devices (Àü´Þ ÀåÄ¡)
- Microspheres and liposomes (¼ÒÇü±¸ ¹× ¸®Æ÷Á»)
- Polymer matrices (秂͟)
- Targeted drug delivery (¸ñÇ¥ ¾à¹° Àü´Þ)
+ Support Services (Áö¿ø ¼ºñ½º)
¿ì¸®ÀÇ ±¤¹üÀ§ÇÑ °³¹ß ÇÁ·Î±×·¥ÀÇ ºÎºÐÀ¸·Î¼, Âû½º¸®¹ö´Â ¾Æ·¡¿Í °°Àº ¸¹Àº Áö¿ø ÇÁ·Î±×·¥À» Á¦°øÇÑ´Ù
- Rapid formulation development to support metabolism and pharmacokinetics services
(´ë»ç ¹× ¾à¹° µ¿ÅÂÇÐ ¼ºñ½ºÀÇ Áö¿øÀ» À§ÇÑ ±Þ¼ÓÇÑ Á¦Ç° °³¹ß)
- Efficacy development in various animal models (´Ù¾çÇÑ µ¿¹°¸ðµ¨¿¡¼ÀÇ À¯È¿¼º °³¹ß)
- Inhalation toxicology (ÈíÀÔµ¶¼º)
- Technical transfer, scale-up, and manufacturing support (±â¼úÀÌÀü, scale-up ¹× Á¦Á¶°øÁ¤ Áö¿ø) |